Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PB101
- Development stage
- Unknown
- Lead developer
- Precision Biotech Taiwan
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
PB101 (also referred to as PB-101) is an autologous cell therapy consisting of natural killer (NK) and natural killer T (NKT) cells, developed by Precision Biotech Taiwan Corp. for the treatment of advanced non-small cell lung cancer (NSCLC). The therapy involves the ex vivo expansion and activation of a patient's own immune cells, which are then re-infused to harness their innate ability to recognize and eliminate malignant cells. PB101 is currently being evaluated in a Phase I clinical trial in combination with standard-of-care EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as osimertinib, gefitinib, erlotinib, or afatinib, specifically for patients with EGFR-mutated advanced NSCLC. This combination approach aims to enhance the therapeutic efficacy of targeted treatments and potentially overcome resistance mechanisms through cellular immunotherapy.
- Other names
- Autologous NK/NKT cell therapy
Beyond the preview
Go deeper on PB101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PB101.